EGFR mutations in patients with advanced NSCLC.
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F12%3A%230000136" target="_blank" >RIV/26475821:_____/12:#0000136 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
EGFR mutations in patients with advanced NSCLC.
Original language description
Genetic testing for the presence of activating EGFR mutations is an essential part of diagnosis of NSCLC and the results have a major impact on the choice of optimal cancer treatment. Molecular targeted therapy with tyrozine kinase inhibitors that blockthe activation cascade of epidermal growth factor receptor (EGFR-TKI), is one of the new modalities of treatment of NSCLC with advanced stage. In our study, analysis of patients survival with EGFR-TKI treatment showed significantly better profit from this therapy in patients carrying activating mutations of EGFR. The incidence of activating mutations of EGFR gene in NSCLC in our population and also their increased frequency in patients with adenocarcinoma, women and non-smokers correlated with publisheddata in the literature.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NS9718" target="_blank" >NS9718: New possibilities for application of molecular-diagnostic methods for early detection and proper therapy selection of progressing Non-Small Cell Lung Cancer based on detection and monitoring of hypermethylation of specific genes</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů